174 related articles for article (PubMed ID: 17230510)
61. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
Brandes JC; van Engeland M; Wouters KA; Weijenberg MP; Herman JG
Carcinogenesis; 2005 Jun; 26(6):1152-6. PubMed ID: 15760919
[TBL] [Abstract][Full Text] [Related]
62. Mismatch repair polymorphisms and the risk of colorectal cancer.
Berndt SI; Platz EA; Fallin MD; Thuita LW; Hoffman SC; Helzlsouer KJ
Int J Cancer; 2007 Apr; 120(7):1548-54. PubMed ID: 17205513
[TBL] [Abstract][Full Text] [Related]
63. Heredity and DNA methylation in colorectal cancer.
Jass JR
Gut; 2007 Jan; 56(1):154-5. PubMed ID: 17172593
[No Abstract] [Full Text] [Related]
64. Effect of MLH1 -93G>A on gene expression in patients with colorectal cancer.
Funck A; Santos JC; Silva-Fernandes IJ; Rabenhorst SH; Martinez CA; Ribeiro ML
Med Oncol; 2014 Sep; 31(9):160. PubMed ID: 25115745
[TBL] [Abstract][Full Text] [Related]
65. MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer.
Muñiz-Mendoza R; Ayala-Madrigal ML; Partida-Pérez M; Peregrina-Sandoval J; Leal-Ugarte E; Macías-Gómez N; Peralta-Leal V; Meza-Espinoza JP; Moreno-Ortiz JM; Ramírez-Ramírez R; Suárez-Villanueva S; Gutiérrez-Angulo M
Genet Mol Res; 2012 Aug; 11(3):2315-20. PubMed ID: 22843073
[TBL] [Abstract][Full Text] [Related]
66. Single-nucleotide polymorphisms of mismatch repair genes in healthy Chinese individuals and sporadic colorectal cancer patients.
Mei Q; Yan HL; Ding FX; Xue G; Huang JJ; Wang YZ; Sun SH
Cancer Genet Cytogenet; 2006 Nov; 171(1):17-23. PubMed ID: 17074586
[TBL] [Abstract][Full Text] [Related]
67. Primary constitutional MLH1 epimutations: a focal epigenetic event.
Dámaso E; Castillejo A; Arias MDM; Canet-Hermida J; Navarro M; Del Valle J; Campos O; Fernández A; Marín F; Turchetti D; García-Díaz JD; Lázaro C; Genuardi M; Rueda D; Alonso Á; Soto JL; Hitchins M; Pineda M; Capellá G
Br J Cancer; 2018 Oct; 119(8):978-987. PubMed ID: 30283143
[TBL] [Abstract][Full Text] [Related]
68. Germline epimutation: A basis for epigenetic disease in humans.
Martin DI; Ward R; Suter CM
Ann N Y Acad Sci; 2005; 1054():68-77. PubMed ID: 16339653
[TBL] [Abstract][Full Text] [Related]
69. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
Huang YW; Liu JC; Deatherage DE; Luo J; Mutch DG; Goodfellow PJ; Miller DS; Huang TH
Cancer Res; 2009 Dec; 69(23):9038-46. PubMed ID: 19887623
[TBL] [Abstract][Full Text] [Related]
70. MutL-homolog 1 expression and risk of incident, sporadic colorectal adenoma: search for prospective biomarkers of risk for colorectal cancer.
Sidelnikov E; Bostick RM; Flanders WD; Long Q; Cohen VL; Dash C; Seabrook ME; Fedirko V
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1599-609. PubMed ID: 19423536
[TBL] [Abstract][Full Text] [Related]
71. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.
Varley KE; Mutch DG; Edmonston TB; Goodfellow PJ; Mitra RD
Nucleic Acids Res; 2009 Aug; 37(14):4603-12. PubMed ID: 19494183
[TBL] [Abstract][Full Text] [Related]
72. A procedure for the detection of linkage with high density SNP arrays in a large pedigree with colorectal cancer.
Middeldorp A; Jagmohan-Changur S; Helmer Q; van der Klift HM; Tops CM; Vasen HF; Devilee P; Morreau H; Houwing-Duistermaat JJ; Wijnen JT; van Wezel T
BMC Cancer; 2007 Jan; 7():6. PubMed ID: 17222328
[TBL] [Abstract][Full Text] [Related]
73. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.
Worrillow LJ; Smith AG; Scott K; Andersson M; Ashcroft AJ; Dores GM; Glimelius B; Holowaty E; Jackson GH; Jones GL; Lynch CF; Morgan G; Pukkala E; Scott D; Storm HH; Taylor PR; Vyberg M; Willett E; Travis LB; Allan JM
J Med Genet; 2008 Mar; 45(3):142-6. PubMed ID: 17959715
[TBL] [Abstract][Full Text] [Related]
74. Re: MLH1 93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer.
Hubner RA; Houlston RS
J Natl Cancer Inst; 2007 Oct; 99(19):1490; author reply 1490-1. PubMed ID: 17895478
[No Abstract] [Full Text] [Related]
75. Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
Lacey JV; Yang H; Gaudet MM; Dunning A; Lissowska J; Sherman ME; Peplonska B; Brinton LA; Healey CS; Ahmed S; Pharoah P; Easton D; Chanock S; Garcia-Closas M
Gynecol Oncol; 2011 Feb; 120(2):167-73. PubMed ID: 21093899
[TBL] [Abstract][Full Text] [Related]
76. MethyLight: a high-throughput assay to measure DNA methylation.
Eads CA; Danenberg KD; Kawakami K; Saltz LB; Blake C; Shibata D; Danenberg PV; Laird PW
Nucleic Acids Res; 2000 Apr; 28(8):E32. PubMed ID: 10734209
[TBL] [Abstract][Full Text] [Related]
77. MLH3 mutation in endometrial cancer.
Taylor NP; Powell MA; Gibb RK; Rader JS; Huettner PC; Thibodeau SN; Mutch DG; Goodfellow PJ
Cancer Res; 2006 Aug; 66(15):7502-8. PubMed ID: 16885347
[TBL] [Abstract][Full Text] [Related]
78. DNA methylation profiles of female steroid hormone-driven human malignancies.
Campan M; Weisenberger DJ; Laird PW
Curr Top Microbiol Immunol; 2006; 310():141-78. PubMed ID: 16909910
[TBL] [Abstract][Full Text] [Related]
79. Short-term folate supplementation in physiological doses has no effect on ESR1 and MLH1 methylation in colonic mucosa of individuals with adenoma.
Al-Ghnaniem Abbadi R; Emery P; Pufulete M
J Nutrigenet Nutrigenomics; 2012; 5(6):327-38. PubMed ID: 23328702
[TBL] [Abstract][Full Text] [Related]
80. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice.
Banno K; Kisu I; Yanokura M; Masuda K; Ueki A; Kobayashi Y; Susumu N; Aoki D
Epigenomics; 2012 Apr; 4(2):147-62. PubMed ID: 22449187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
